Abstract:UBackground: The bromodomain and extra-terminal proteins (BET), in particular BRD4, has recently emerged as a potential therapeutic target for the treatment of many human disorders such as cancer, inflammation, obesity and cardiovascular disease, which draw more and more attention to discover potent BRD4 inhibitors in the past years. In this article, we described the discovery process of an entirely new chemotype of BRD4 inhibitors. Methods: A fragment-based drug discovery strategy was employed in attempting to find a novel chemotype of BRD4 inhibitors. Thus, the potential hits were firstly identified by docking study with KAc binding pocket and AlphaScreen assay. Then the elected hit was further structurally optimized based on the interaction revealed by the docking study and the Structure-Activity Relationship (SAR). Results: A 1-(2-hydroxyphenyl)ethan-1-one fragment was first identified as an efficient hit to BRD4 with a weak inhibition activity and high ligand efficiency (IC50 = 8.9 mu M LE > 0.5) based on virtual screening and biochemical assay. Then, two-rounds optimization of the hit by a fragment-based drug discovery approach enabled the discovery of a potent BRD4 inhibitor 9, which exhibit nanomolar potency in biochemical assays (IC50 = 0.18 mu M). Conclusion: The title compounds displayed potent inhibitory activity to BRD4, implying acetophenone core is an effective KAc residue mimic, suggesting acetophenone derivatives as a new chemotype may be promising for developing novel BRD4 inhibitors.

Discovery of the Natural Product 3',4',7,8-Tetrahydroxyflavone As a Novel and Potent Selective BRD4 Bromodomain 2 Inhibitor.

Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria Sp. NH-F6.

The Natural Product 3',4',7,8- Tetrahydroxyflavonoid is a Potent BRD4-BD2 Inhibitor in Suppressing Acute Myeloid Leukemia

Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site

Design, Synthesis and Biological Evaluation of Novel 6-Phenyl-1,3a,4,10b-tetrahydro-2h-benzo[c]thiazolo[4,5-e]azepin-2-one Derivatives As Potential BRD4 Inhibitors.

Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation

Design, Synthesis, and Biological Evaluation of Novel 4,4-Difluoro-1-methyl-n, 6-Diphenyl-5, 6-Dihydro-4h-pyrimido [4, 5-B] [1, 2, 4] Triazolo [4, 3-D] [1, 4] Diazepin-8-amine Derivatives As Potential BRD4 Inhibitors.

Design, synthesis and biological evaluation of 3,5-dimethylisoxazole and pyridone derivatives as BRD4 inhibitors.

Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors

Discovery Of 3,5-Dimethylisoxazole Derivatives As Novel, Potent Inhibitors For Bromodomain And Extraterminal Domain (Bet) Family

Design, Synthesis and Biological Evaluation of Dihydroquinoxalinone Derivatives As BRD4 Inhibitors.

Bromodomain-Containing Protein 4: A Druggable Target.

Drug Discovery of Acetophenone Derivatives As BRD4 Inhibitors

Drug Discovery Targeting Bromodomain-Containing Protein 4

Discovery of the First BRD4 Second Bromodomain (BD2)-Selective Inhibitors

Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases

Design, Synthesis and Biological Evaluation of Novel 4,5-Dihydro-[1,2,4]triazolo[4,3-f]pteridine Derivatives As Potential BRD4 Inhibitors.

Discovery of Novel Coumarin Derivatives As Potent and Orally Bioavailable BRD4 Inhibitors Based on Scaffold Hopping

Development of 4,5-Dihydro-benzodiazepinone Derivatives As A New Chemical Series of Brd4 Inhibitors

Development of 7-Methylimidazo[1,5-a]pyrazin-8(7h)-one Derivatives As a Novel Chemical Series of BRD4 Inhibitors

Design, synthesis and biological evaluation of coumarin derivatives as potential BRD4 inhibitors